Beta Drugs Ltd
BETABeta Drugs Ltd's price has outrun its earnings. +32.5% in a year against EPS −2.6% — the market is paying now for delivery later.
The sharpest disagreement: the price moved +32.5% in a year while annual EPS moved −2.6% — the difference is re-rating, and re-rating has to be repaid with earnings.
The price is in a confirmed uptrend (3 weeks in) while the P/E sits at the 96th percentile of its own 7-year range. Underneath, the last four quarters read improving — profit +33.3% year on year, and 87% of the last 3 years' profit arrived as cash. What settles it: whether earnings grow into a price that has already moved.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Beta Drugs Ltd trades at ₹2,229, in a confirmed uptrend and 3 weeks into that stage. That is +38.3% against its own 200-day average. It sits at 90% of a 52-week range of ₹1,052 to ₹2,367. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 14 straight weeks.
Today the stock is in a confirmed uptrend — week 3 of stage 2, confirmed. At ₹2,229 it trades +38.3% versus its 200-day average and sits at 90% of its 52-week range (₹1,052–₹2,367).
Against the market, two honest reads. Cumulative: over the last 8.8 years the stock moved +2,154% while the NIFTY 500 moved +160% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 14 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
→ The trend is one thing; the bill is another. Are you paying up for it? Next: the P/E sits at the 96th percentile of its own range.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Beta Drugs Ltd trades at 52.9× P/E, at the pricey end of its own range (96th percentile). Its long-run median P/E is 30.8×, measured across 6.8 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 52.9× is at the pricey end of its own range (96th percentile), against a long-run median of 30.8× measured over 6.8 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
🚨 Why the multiple sits where it does: over the past year annual EPS moved −2.6% against a +32.5% price move — the price outran earnings, pushing the multiple UP its own range.
The price move, decomposed: over 5y, of the +43.3%/yr price move, ~+30.9%/yr came from earnings growth and ~+12.4 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
A quarterly PEG curve, which only the second data source carries, is not drawn on this page: its two data sources disagree by up to 50% on reported income across 11 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
→ Cheap or dear rides on the earnings. Are they actually growing? Next: the fundamental stage — where the business sits in its arc, and how growth has compounded.
Stage: Turning around Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Beta Drugs Ltd reads as turning around on its fundamental arc. Turning around — profit growth swung from −40.0% at the trough to −14.8%, a 2-quarter improving streak, ROCE slipping at 19.0%. The read is built from 11 quarters across 4 curves, on partial evidence.
Why it matters: growth inflections are where re-ratings start — the curves say a turn is forming, so the question becomes whether the next quarters confirm it.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
A partial read: at least one curve is short, or the returns curve is not the computed quarterly series — hold the stage word a little more loosely.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +6.4% | +19.3% | +27.1% | +30.9% |
| Profit | −2.4% | +9.8% | +27.9% | +45.0% |
| EPS | −2.6% | +10.4% | +28.7% | +14.8% |
| Share price | +32.5% | +46.1% | +43.3% | — |
→ The stage names the trajectory. Next: the revenue line that produces it, quarter by quarter.
4-Factor Sector Score
43.0/100 — rank 10 of 14 in Pharma - API · 77% evidence confidence
Beta Drugs Ltd scores 43.0 out of 100 against the 14 companies it is compared with in Pharma - API, ranking 10. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 11.5 + 15.9 + 7.4 + 8.2 = 43. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Beta Drugs Ltd reported ₹126 Cr of revenue in the Jun 26 quarter, +26.0% year on year. Over 10 years it has compounded at 30.9% a year. The last full year, FY26, came in at ₹385 Cr. The last four reported quarters add to ₹410 Cr.
Beta Drugs Ltd reported ₹126 Cr of revenue in the Jun 26 quarter, +26.0% year on year. Over 10 years it has compounded at 30.9% a year. The last full year, FY26, came in at ₹385 Cr. The last four reported quarters add to ₹410 Cr.
FY26 revenue came in at ₹385 Cr (+6.4% on the year), capping 10 years at 30.9% compound. The latest quarter (Jun 26) printed ₹126 Cr, +26.0% year on year.
Pace check: the last four quarters averaged −4.5% growth against the decade's 30.9% — the current year is running slower than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew −11.3% over the last 4 quarters against −11.4%/yr over the last 8 — stabilising; TTM profit −14.8% vs −17.8%/yr — stabilising.
→ Revenue grew — did margins hold as it scaled? Next: 22.0% this quarter (+2.0 pp YoY).
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Beta Drugs Ltd's operating margin is 22.0% in the Jun 26 quarter, +2.0 percentage points against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 0.0% to 23.0%. The current quarter sits inside that band.
Beta Drugs Ltd's operating margin is 22.0% in the Jun 26 quarter, +2.0 percentage points against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 0.0% to 23.0%. The current quarter sits inside that band.
The latest quarter's operating margin is 22.0%, +2.0 pp against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 0.0%–23.0%.
Why the margin moved: operating margin went +2.1 pp year on year while gross margin went +6.2 pp — the gain came mostly from the gross line: input costs and pricing.
→ Margins held — did that reach the bottom line? Next: profit +33.3% in the latest quarter.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Beta Drugs Ltd earned ₹16.0 Cr of net profit in the Jun 26 quarter, +33.3% year on year. Full-year FY26 profit was ₹41.0 Cr. The 10-year compound rate is 45.0%. That is 12.7% of the quarter's revenue. The same quarter a year earlier earned ₹12.0 Cr.
Beta Drugs Ltd earned ₹16.0 Cr of net profit in the Jun 26 quarter, +33.3% year on year. Full-year FY26 profit was ₹41.0 Cr. The 10-year compound rate is 45.0%. That is 12.7% of the quarter's revenue. The same quarter a year earlier earned ₹12.0 Cr.
Jun 26 profit was ₹16.0 Cr, +33.3% year on year. On the full year, FY26 printed ₹41.0 Cr (−2.4%), and the 10-year compound rate is 45.0%.
Why profit moved: revenue contributed +26.0% and the margin +2.0 pp — the quarter was margin-led: most of the profit growth came from keeping more of each sale.
Pace comparison, last four quarters: profit −4.2% vs revenue −4.5%. Profit and revenue are moving roughly in step.
→ Profit rose — but did the cash follow? Next: 87% of the last 3 years' profit arrived as cash.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 87% of Beta Drugs Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹37.0 Cr of operating cash against ₹41.0 Cr of profit. After ₹53.0 Cr of capital spending, ₹−16.0 Cr was left as free cash.
FY26: operating cash of ₹37.0 Cr against reported profit of ₹41.0 Cr, leaving free cash of ₹−16.0 Cr after ₹53.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 87% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 87%: the cash cycle stretched 21 days between FY21 and FY26 — more of each rupee of profit waits inside the cycle before arriving.
Router verdict: the bigger cash user is investment — capital spending ran 2.5× depreciation over three years, so the next section's job is to check what that build-out is buying.
→ So follow the cash to where it goes. Next: ₹102 Cr of building over 3 years.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Beta Drugs Ltd's cash conversion cycle runs 100 days in FY26, up from 79 days in FY21. Capital spending ran ₹102 Cr over the last 3 years. At FY26 sales of ₹385 Cr each day of that cycle holds about ₹1.1 Cr, so roughly ₹105 Cr sits inside the business at any moment.
FY26: debtors at 113 days, inventory at 159 days — roughly 5.2 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 100 days, looser than FY21's 79.
The full loop: cash goes out to suppliers and production on day 0; stock waits 159 days to sell; customers pay about 113 days after that; and suppliers themselves are paid at 172 days — netting out to the 100-day cycle.
In money terms: at FY26 sales of ₹385 Cr, each day of the cycle holds about ₹1.1 Cr — so the 100-day loop keeps roughly ₹105 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹102 Cr over the last 3 fiscal years against ₹40.0 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹0.0 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
→ Does all this activity actually earn its cost of capital? Next: ROCE is 19%.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
Beta Drugs Ltd earns a ROCE of 19% in FY26. That is up from a trough of −3% in FY15. A return-on-invested-capital spread against the cost of capital is not computable from what is held here. The wiring behind it is 10.6% net margin on 0.78× asset turns.
FY26 ROCE is 19%, recovered from a FY15 trough of −3% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY26): 10.6% net margin × 0.78× asset turns × 2.02× balance-sheet leverage ≈ 16.7% on equity. Margin does its share; leverage is a meaningful part of the equation.
The quarterly return curves and the return-on-invested-capital overlay, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 50% on reported income across 11 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
→ Returns like these — is the balance sheet borrowing to make them? Next: debt-to-equity is 0.60.
Debt Debt-to-equity says how much of the business is funded by borrowings; interest cover says how many times operating profit pays the interest bill. Low and high, respectively, is the safe corner.
Beta Drugs Ltd carries ₹148 Cr of borrowings against ₹245 Cr of equity in FY26, a debt-to-equity of 0.60. Operating profit covers the interest bill 5×. Over 5 years borrowings went from ₹17.0 Cr to ₹148 Cr. Capital spending ran ₹102 Cr across the last 3 of those years.
FY26: borrowings of ₹148 Cr against equity of ₹245 Cr — a debt-to-equity of 0.60. Operating profit covers the interest bill 5×. Over 5 years borrowings went from ₹17.0 Cr to ₹148 Cr while capital spending ran ₹102 Cr in just the last 3 — part of the build-out is riding on borrowed money.
The total-debt and debt-to-equity series, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 50% on reported income across 11 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
→ Who owns this, and are they adding or leaving? Next: Promoters cut 7.6 points over 8 quarters.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Promoters cut 7.6 points of Beta Drugs Ltd over 8 quarters, the biggest move on the register. That takes promoters to 59.1% of the company. Domestic institutions moved +6.1 points over the same window, to 6.2%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Promoters: −7.6 points over 8 quarters to 59.1%; Domestic institutions: +6.1 points over 8 quarters to 6.2%; Foreign institutions: −0.1 points over 8 quarters to 1.0%.
🚨 Why the register moved: promoters drove it (−7.6 points), absorbed on the other side by domestic institutions (+6.1 points) — distribution into the market’s bid.
→ One last check: does the safety math agree? Next: the balance-sheet safety line.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Beta Drugs Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | P/E | Mkt cap | Revenue | EPS | ROCE | Stage |
|---|---|---|---|---|---|---|
| Beta Drugs Ltd this page | 52.9× | ₹2,413 Cr | Turning around | |||
| Senores Pharmaceuticals Ltd | 55.4× | ₹6,390 Cr | No read | |||
| Aarti Pharmalabs Ltd | 34.6× | ₹6,110 Cr | Mixed | |||
| Innova Captab Ltd | 38.8× | ₹5,439 Cr | Consistent | |||
| Orchid Pharma Ltd | 185.0× | ₹5,014 Cr | Turning around | |||
| Gujarat Themis Biosyn Ltd | 84.2× | ₹3,928 Cr | Turning around | |||
| Aarti Drugs Ltd | 18.9× | ₹3,692 Cr | Mixed | |||
| Ind-Swift Laboratories Ltd | 40.0× | ₹1,978 Cr | No read | |||
| Jagsonpal Pharmaceuticals Ltd | 32.7× | ₹1,461 Cr | Mixed | |||
| Fermenta Biotech Ltd | 20.2× | ₹1,272 Cr | No read | |||
| Wanbury Ltd | 27.0× | ₹1,160 Cr | Turning around | |||
| Themis Medicare Ltd | 613.0× | ₹1,012 Cr | Mixed | |||
| Fermenta Biotech Ltd | 11.2× | ₹989 Cr | No read | |||
| Kopran Ltd | 37.3× | ₹960 Cr | Turning around | |||
| Anuh Pharma Ltd | 21.8× | ₹792 Cr | Turning around |
Frequently asked questions
What is Beta Drugs Ltd's share price today?
Beta Drugs Ltd trades at ₹2,229, +32.5% over the past year. The company is valued at ₹2,413 Cr. The stock sits at 90% of its 52-week range of ₹1,052–₹2,367, +38.3% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 3 weeks in. — as of 24 July 2026.
What were Beta Drugs Ltd's latest quarterly results?
Beta Drugs Ltd reported revenue of ₹126 Cr and net profit of ₹16.0 Cr for the Jun 26 quarter. Revenue rose 26.0% and profit rose 33.3% year on year. Earnings per share were ₹15.16. The operating margin was 22.0%, 2.0 pp higher than a year earlier. — as of 24 July 2026.
What is Beta Drugs Ltd's revenue?
Beta Drugs Ltd reported revenue of ₹126 Cr in the Jun 26 quarter, +26.0% year on year. For the full FY26 fiscal year, revenue was ₹385 Cr (+6.4%). Over the last 10 years revenue compounded at 30.9% a year. — as of 24 July 2026.
What is Beta Drugs Ltd's profit?
Beta Drugs Ltd earned ₹16.0 Cr of net profit in the Jun 26 quarter, +33.3% year on year. Full-year FY26 profit was ₹41.0 Cr. The operating margin ran 22.0% in the latest quarter. — as of 24 July 2026.
What is Beta Drugs Ltd's market cap?
Beta Drugs Ltd's market capitalisation is ₹2,413 Cr at a share price of ₹2,229. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 24 July 2026.
What is Beta Drugs Ltd's P/E ratio?
Beta Drugs Ltd trades at a P/E of 52.9×, at the 96th percentile of its own 7-year range, against a long-run median of 30.8×. This is a comparison with the stock's own history, not a value call — as of 24 July 2026.
Does Beta Drugs Ltd pay a dividend?
No — Beta Drugs Ltd has recorded a dividend payout of 0% of profit in each of its last 13 reported fiscal years, so there is no payout history to quote. That is a reading of the filed annual statements, not an estimate. — as of 24 July 2026.
Is Beta Drugs Ltd overvalued?
On its own history, Beta Drugs Ltd looks expensive against its own history: its P/E of 52.9× sits at the 96th percentile of its 7-year range (long-run median 30.8×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 24 July 2026.
Is Beta Drugs Ltd growing?
Yes — Beta Drugs Ltd is growing: latest-quarter revenue +26.0% year on year, profit +33.3%, and the margin +2.0 pp at 22.0%. The 10-year compound rates are 30.9% (revenue) and 45.0% (profit). The earnings engine currently reads: improving — as of 24 July 2026.
How is Beta Drugs Ltd performing?
Beta Drugs Ltd is in a confirmed uptrend, 3 weeks in. Its latest quarter's revenue rose 26.0% and profit rose 33.3% year on year. Against the NIFTY 500 it has been ahead on a trailing-13-week view for 14 weeks. This describes what the data did, not a rating. — as of 24 July 2026.
What stage is Beta Drugs Ltd in?
Turning around — profit growth swung from −40.0% at the trough to −14.8%, a 2-quarter improving streak, ROCE slipping at 19.0%. The read comes from the last 12 quarters of growth (revenue growth −11.3% latest, profit growth −14.8% latest, eps growth −16.8% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 24 July 2026.
Is Beta Drugs Ltd in an uptrend?
Yes — the price is in a confirmed uptrend (week 3 of stage 2), trading +38.3% versus its 200-day average and at 90% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 24 July 2026.
Is Beta Drugs Ltd beating the market?
On recent form, yes — Beta Drugs Ltd has been ahead of the NIFTY 500 on a trailing-13-week view for 14 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 8.8 years the stock moved +2,154% against the NIFTY 500's +160% — ahead of the index over the full window. — as of 24 July 2026.
Will Beta Drugs Ltd's share price go up?
This page publishes no price forecast for Beta Drugs Ltd. What it measures instead: the share price is ₹2,229, the price is in a confirmed uptrend 3 weeks in. Its P/E of 52.9× sits at the 96th percentile of its own 7-year range. — as of 24 July 2026.
Who owns Beta Drugs Ltd?
Promoters hold 59.1% of Beta Drugs Ltd, foreign institutions 1.0%, domestic institutions 6.2% and the public 33.6% (latest quarter). The biggest move on the register over the last two years: Promoters cut 7.6 points over 8 quarters. — as of 24 July 2026.
Does Beta Drugs Ltd have too much debt?
It is moderate — Beta Drugs Ltd's debt-to-equity is 0.60, and operating profit covers the interest bill 5×. FY26 borrowings were ₹148 Cr against equity of ₹245 Cr. Read the returns on this page with that leverage in mind — as of 24 July 2026.
What is Beta Drugs Ltd's capex?
Beta Drugs Ltd spent ₹102 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹53.0 Cr, with ₹0.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 24 July 2026.
What is Beta Drugs Ltd's cash flow?
Beta Drugs Ltd generated ₹37.0 Cr of operating cash flow in FY26 and ₹−16.0 Cr of free cash flow after ₹53.0 Cr of capital spending. Reported profit that year was ₹41.0 Cr, so operating cash ran behind profit. Cash-flow resolution for India is annual. — as of 24 July 2026.
Is Beta Drugs Ltd's profit real cash?
Yes — over the last 3 fiscal years, 87% of Beta Drugs Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹37.0 Cr against reported profit of ₹41.0 Cr. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 24 July 2026.
Where is Beta Drugs Ltd in its business cycle?
Beta Drugs Ltd's FY26 operating margin was 20.0%, against a 13-year band of 0.0%–23.0%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 22.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 24 July 2026.
What could break the Beta Drugs Ltd story?
The sharpest disagreement: the price moved +32.5% in a year while annual EPS moved −2.6% — the difference is re-rating, and re-rating has to be repaid with earnings. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 24 July 2026.
Is Beta Drugs Ltd a stock worth studying right now?
This is not investment advice. The machine read: Beta Drugs Ltd's price has outrun its earnings. +32.5% in a year against EPS −2.6% — the market is paying now for delivery later. The sharpest open question: whether earnings grow into a price that has already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 24 July 2026.